U.S. markets open in 5 hours 41 minutes
  • S&P Futures

    4,374.50
    -37.25 (-0.84%)
     
  • Dow Futures

    34,832.00
    -142.00 (-0.41%)
     
  • Nasdaq Futures

    14,840.00
    -197.75 (-1.32%)
     
  • Russell 2000 Futures

    2,222.00
    -15.50 (-0.69%)
     
  • Crude Oil

    73.32
    -0.30 (-0.41%)
     
  • Gold

    1,834.50
    -1.30 (-0.07%)
     
  • Silver

    25.64
    -0.14 (-0.55%)
     
  • EUR/USD

    1.1901
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.2690
    0.0000 (0.00%)
     
  • Vix

    19.44
    +1.13 (+6.17%)
     
  • GBP/USD

    1.3964
    +0.0006 (+0.04%)
     
  • USD/JPY

    109.5100
    +0.0490 (+0.04%)
     
  • BTC-USD

    39,835.93
    -139.93 (-0.35%)
     
  • CMC Crypto 200

    946.22
    +15.86 (+1.70%)
     
  • FTSE 100

    7,009.58
    -68.84 (-0.97%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

BetterLife Pharma to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

·3 min read

VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA:NPAU), an emerging biotech company focused on non-hallucinogenic psychedelic therapeutics, today announced that Ahmad Doroudian, Chief Executive Officer, will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021.

The conference will be held virtually and Dr. Doroudian will provide details of the Company’s product development and pipeline.

Details of the presentation are as follows:

Date: Thursday, June 17th, 2021
Time: BetterLife’s presentation will be available to access on-demand beginning at 7:00 a.m. EDT
Registration: https://hcwevents.com/psychedelics/

About BetterLife Pharma Inc.

BetterLife Pharma Inc. is an emerging biotechnology company engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. BetterLife is refining and developing drug candidates from a broad set of complementary interferon-based technologies which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer.

For further information please visit www.abetterlifepharma.com.

Contact Information:

Ahmad Doroudian, Chief Executive Officer
Email: Ahmad.Doroudian@blifepharma.com
Phone: 604-221-0595

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.